Dimerix Ltd has released a press release.
Quarterly Review & Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Dimerix
- Ethics Approval Received Appendix 3B and S.708A Notice
- Further US patent allowed for DMX-200
- Dual Phase 2 trials launched for CKD
- Westar Capital Retained as Corporate Advisors
- CMO Appointment and Clinical Trials Update
Later from Dimerix
- Executive team bolstered through CEO & md appointment
- First patient dosed in dmx-200 clinical trial
- DXB Receives Orphan Drug Designation in EU
- 1st Patient Dosed in DMX-200 Clinical Trial for FSGS
- Dimerix Receives R&D Tax Cash Rebate Totalling $1.07m
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix